Why Zoetis (ZTS) Is Down 10.4% After Trimming 2026 Outlook Amid Weaker Pet Demand

• Zoetis Inc. reported past Q1 2026 results with sales of US$2,262 million and net income of US$601 million, while also revising its full‑year 2026 outlook to revenue of US$9.68–US$9.96 billion and reported diluted EPS of US$6.35–US$6.50.
• Alongside softer U.S. companion animal demand and increased competition, several Zoetis directors recently bought shares on the open market, highlighting insider confidence during a period of operational headwinds.
• We will now examine how Zoetis’s weaker U.S. companion animal performance and reduced 2026 guidance affect its previously optimistic investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Zoetis Investment Narrative Recap

To own Zoetis today, you need to believe its core animal health franchises and R&D engine can justify riding out a difficult period for U.S. companion animal demand. The key short term catalyst is whether management can stabilize that segment after a sharp guidance cut, while the biggest risk is that competitive and pricing pressure in key pet products proves more structural than temporary. The Q1 reset meaningfully weakens, but does not fully break, the original bullish narrative.

The updated 2026 guidance to US$9.68–US$9.96 billion in revenue and diluted EPS of US$6.35–US$6.50 sits at the center of this debate. It directly tests earlier expectations that Zoetis could combine steady organic growth with margin resilience, and it reframes catalysts around execution: regaining momentum in U.S. companion animals, integrating Neogen’s animal genomics acquisition as planned in H2 2026, and proving that its innovation pipeline can offset rising competition.

Yet beneath the insider buying and pipeline ambitions, one issue investors should be aware of is the risk that intensifying generic and biotech competition in core franchises could...

Read the full narrative on Zoetis (it's free!)

Zoetis' narrative projects $10.9 billion revenue and $3.2 billion earnings by 2028. This requires 5.2% yearly revenue growth and about a $0.6 billion earnings increase from $2.6 billion today.

Uncover how Zoetis' forecasts yield a $151.00 fair value, a 103% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming revenue would reach about US$10.6 billion and earnings around US$3.2 billion by 2029, and they see much higher regulatory and competitive risks than the baseline view. If you are focusing on softer U.S. companion animal demand and heightened price sensitivity, this more pessimistic narrative shows how sharply opinions can differ and why both sets of assumptions may need revisiting after the latest results.

Explore 9 other fair value estimates on Zoetis - why the stock might be worth just $127.00!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zoetis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com